Julkaisut

2021

  1. Moore, KN, Bookman, M, Sehouli, J, Miller, A, Anderson, C, Scambia, G et al.. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39 (17):1842-1855. doi: 10.1200/JCO.21.00306. PubMed PMID:33891472 PubMed Central PMC8189598.
  2. Callens, C, Vaur, D, Soubeyran, I, Rouleau, E, Just, PA, Guillerm, E et al.. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. J Natl Cancer Inst. 2021;113 (7):917-923. doi: 10.1093/jnci/djaa193. PubMed PMID:33372675 PubMed Central PMC8246800.
  3. Veijalainen, O, Kares, S, Kotaniemi-Talonen, L, Kujala, P, Vuento, R, Luukkaala, T et al.. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstet Gynecol Scand. 2021;100 (3):403-409. doi: 10.1111/aogs.14021. PubMed PMID:33037625 .

Search PubMed

2020

  1. Jäntti, T, Luhtala, S, Mäenpää, J, Staff, S. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer. Tumour Biol. 2020;42 (11):1010428320971404. doi: 10.1177/1010428320971404. PubMed PMID:33169632 .
  2. Veijalainen, O, Kares, S, Kotaniemi-Talonen, L, Kujala, P, Vuento, R, Luukkaala, T et al.. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstet Gynecol Scand. 2021;100 (3):403-409. doi: 10.1111/aogs.14021. PubMed PMID:33037625 .
  3. Savolainen, K, Scaravilli, M, Ilvesmäki, A, Staff, S, Tolonen, T, Mäenpää, JU et al.. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020;13 (1):311. doi: 10.1186/s13104-020-05155-6. PubMed PMID:32611374 PubMed Central PMC7329467.
  4. Kuittinen, T, Rovio, P, Luukkaala, T, Laurila, M, Grénman, S, Kallioniemi, A et al.. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro. Anticancer Res. 2020;40 (6):3129-3138. doi: 10.21873/anticanres.14294. PubMed PMID:32487607 .
  5. Huttala, O, Staff, S, Heinonen, T, Mäenpää, J, Tanner, M, Ylikomi, T et al.. In Vitro Vascular Network Modified to Function as Culture Platform and Angiogenic Induction Potential Test for Cancer Cells. Int J Mol Sci. 2020;21 (5):. doi: 10.3390/ijms21051833. PubMed PMID:32155897 PubMed Central PMC7084873.
  6. Rohr, I, Alavi, S, Richter, R, Keller, M, Chekerov, R, Oskay-Özcelik, G et al.. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). Int J Gynecol Cancer. 2020;30 (4):509-514. doi: 10.1136/ijgc-2019-000892. PubMed PMID:32139438 .
  7. Aalto, A, Huotari-Orava, R, Luhtala, S, Mäenpää, J, Staff, S. Expression of Estrogen-Related Receptors in Localized Provoked Vulvodynia. Biores Open Access. 2020;9 (1):13-21. doi: 10.1089/biores.2019.0049. PubMed PMID:32117596 PubMed Central PMC7047250.
  8. Vuorinen, RK, Luukkaala, TH, Mäenpää, JU. The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice. Acta Oncol. 2020;59 (4):453-457. doi: 10.1080/0284186X.2019.1711175. PubMed PMID:31920123 .
  9. Antila, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study. Eur J Obstet Gynecol Reprod Biol. 2020;244 :134-140. doi: 10.1016/j.ejogrb.2019.11.021. PubMed PMID:31785470 .

Search PubMed

2019

  1. Ray-Coquard, I, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Berger, R et al.. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381 (25):2416-2428. doi: 10.1056/NEJMoa1911361. PubMed PMID:31851799 .
  2. Antila, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study. Eur J Obstet Gynecol Reprod Biol. 2020;244 :134-140. doi: 10.1016/j.ejogrb.2019.11.021. PubMed PMID:31785470 .
  3. González-Martín, A, Pothuri, B, Vergote, I, DePont Christensen, R, Graybill, W, Mirza, MR et al.. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381 (25):2391-2402. doi: 10.1056/NEJMoa1910962. PubMed PMID:31562799 .
  4. Mirza, MR, Åvall Lundqvist, E, Birrer, MJ, dePont Christensen, R, Nyvang, GB, Malander, S et al.. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20 (10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. PubMed PMID:31474354 .
  5. Kares, S, Veijalainen, O, Kholová, I, Tirkkonen, M, Vuento, R, Huhtala, H et al.. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?. APMIS. 2019;127 (11):710-716. doi: 10.1111/apm.12990. PubMed PMID:31403733 .
  6. Mirza, MR, Bergmann, TK, Mau-Sørensen, M, Christensen, RD, Åvall-Lundqvist, E, Birrer, MJ et al.. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019;84 (4):791-798. doi: 10.1007/s00280-019-03917-z. PubMed PMID:31375879 .
  7. Falconer, H, Palsdottir, K, Stalberg, K, Dahm-Kähler, P, Ottander, U, Lundin, ES et al.. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. Int J Gynecol Cancer. 2019;29 (6):1072-1076. doi: 10.1136/ijgc-2019-000558. PubMed PMID:31203203 .
  8. Aalto, AP, Huhtala, H, Mäenpää, J, Staff, S. Combination of Treatments With or Without Surgery in Localized Provoked Vulvodynia: Outcomes After Three Years of Follow-Up. Biores Open Access. 2019;8 (1):25-31. doi: 10.1089/biores.2018.0044. PubMed PMID:30867980 PubMed Central PMC6415354.
  9. Bhatla, N, Berek, JS, Cuello Fredes, M, Denny, LA, Grenman, S, Karunaratne, K et al.. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145 (1):129-135. doi: 10.1002/ijgo.12749. PubMed PMID:30656645 .
  10. Veijalainen, O, Kares, S, Kujala, P, Vuento, R, Osuala, V, Tirkkonen, M et al.. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30 (2):150-156. doi: 10.1111/cyt.12652. PubMed PMID:30421573 .

Search PubMed

2018

  1. Veijalainen, O, Kares, S, Kujala, P, Vuento, R, Osuala, V, Tirkkonen, M et al.. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30 (2):150-156. doi: 10.1111/cyt.12652. PubMed PMID:30421573 .
  2. Niemi, RJ, Braicu, EI, Kulbe, H, Koistinen, KM, Sehouli, J, Puistola, U et al.. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br J Cancer. 2018;119 (7):847-854. doi: 10.1038/s41416-018-0270-z. PubMed PMID:30293997 PubMed Central PMC6189177.
  3. Niemi, RJ, Roine, AN, Eräviita, E, Kumpulainen, PS, Mäenpää, JU, Oksala, N et al.. FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer. Gynecol Oncol. 2018;151 (3):519-524. doi: 10.1016/j.ygyno.2018.09.016. PubMed PMID:30257785 .
  4. Antila-Långsjö, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Cesarean scar defect: a prospective study on risk factors. Am J Obstet Gynecol. 2018;219 (5):458.e1-458.e8. doi: 10.1016/j.ajog.2018.09.004. PubMed PMID:30240650 .
  5. Antila-Långsjö, R, Mäenpää, JU, Huhtala, H, Tomás, E, Staff, S. Comparison of transvaginal ultrasound and saline contrast sonohysterography in evaluation of cesarean scar defect: a prospective cohort study. Acta Obstet Gynecol Scand. 2018;97 (9):1130-1136. doi: 10.1111/aogs.13367. PubMed PMID:29754409 .
  6. Mäenpää, MM, Nieminen, K, Tomás, EI, Luukkaala, TH, Mäenpää, JU. Robotic-Assisted Infrarenal Para-aortic Lymphadenectomy in Gynecological Cancers: Technique and Surgical Outcomes. Int J Gynecol Cancer. 2018;28 (5):951-958. doi: 10.1097/IGC.0000000000001249. PubMed PMID:29683877 .

Search PubMed